title: No change of the lipid profile under the control of ApoE gene polymorphism in schizophrenics under paliperidone treatment.
abstract: The present study tried to explore the effects of Paliperidone on the lipid profiles of schizophrenia patients. One hundred twenty-nine subjects diagnosed with schizophrenia were enrolled into this study and completed the lipid profile evaluation. Their blood samples were obtained on the morning following a 12-hours fast. Cholesterol and triglyceride (TG) levels in plasma were determined, and lipoproteins were determined by enzymatic methods. All participants provided written informed consent, and underwent additional venous blood withdrawal for DNA extraction for genetic study of the ApoE gene polymorphism. Under T test, TC, TG and HDL levels all declined after Paliperidone treatment although with no statistically significant difference. The ratios of TC/HDL declined after Paliperidone treatment, but without statistically significant difference. After GEE-I analysis, we found that ApoE4 genotype (β = 34.471; p < 0.001) had a positive effect on the total cholesterol (TC) level; female had positive effect on the high-density lipoprotein (HDL) level (β = 15.361; p = 0.003); and age had a positive effect on the TG level (β = 1.317; p = 0.030). Smoking (β = 0.961; p = 0.016) had a positive effect on the ratio of TC/HDL change. Lipid profiles were not increased after Paliperidone treatment under the control of ApoE gene polymorphism.
authors.affiliation: Department of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan.
authors.forename: Wei-Tsung
authors.initials: WT
authors.lastname: Kao
authors.forename: Chen-Lin
authors.initials: CL
authors.lastname: Chang
authors.forename: Yi-Lung
authors.initials: YL
authors.lastname: Chen
authors.forename: For-Wey
authors.initials: FW
authors.lastname: Lung
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001057:Apolipoproteins E / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D000068882:Paliperidone Palmitate; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011569:Psychiatric Status Rating Scales; D011743:Pyrimidines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy / Q000235:genetics; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001057:Apolipoproteins E; D007555:Isoxazoles; D008055:Lipids; D011743:Pyrimidines; D000068882:Paliperidone Palmitate
references.citation: J Clin Psychiatry. 1994 May;55 Suppl:5-12
references.pmid: 7520908
references.citation: Atherosclerosis. 1996 Feb;120(1-2):67-73
references.pmid: 8645372
references.citation: Clin Chem Lab Med. 1998 Aug;36(8):615-9
references.pmid: 9806471
references.citation: Eur J Epidemiol. 2001;17(8):789-92
references.pmid: 12086099
references.citation: Arterioscler Thromb. 1994 Sep;14(9):1412-9
references.pmid: 8068601
references.citation: Neurology. 1999 Sep 22;53(5):962-6
references.pmid: 10496253
references.citation: Diabetes. 1988 Dec;37(12):1595-607
references.pmid: 3056758
references.citation: J Hypertens. 2002 Oct;20(10):2017-21
references.pmid: 12359980
references.citation: Biometrics. 1986 Mar;42(1):121-30
references.pmid: 3719049
references.citation: Ann Epidemiol. 2000 Nov;10(8):524-31
references.pmid: 11118932
references.citation: Am J Hum Genet. 1988 Jan;42(1):104-12
references.pmid: 3337104
references.citation: J Clin Psychiatry. 2003 May;64(5):575-9
references.pmid: 12755662
references.citation: Eur Arch Psychiatry Clin Neurosci. 2000;250(6):274-85
references.pmid: 11153962
references.citation: J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
references.pmid: 9881538
references.citation: Clin Genet. 1986 Jun;29(6):477-84
references.pmid: 3461894
references.citation: Metabolism. 2004 Jan;53(1):108-16
references.pmid: 14681851
references.citation: Clin Genet. 1995 Sep;48(3):113-9
references.pmid: 8556815
references.citation: J Lipid Res. 2000 Aug;41(8):1290-301
references.pmid: 10946017
references.citation: Atherosclerosis. 2003 Oct;170(2):253-60
references.pmid: 14612205
references.citation: Atherosclerosis. 1995 Apr 7;114(1):55-9
references.pmid: 7605376
references.citation: Science. 1988 Apr 29;240(4852):622-30
references.pmid: 3283935
references.citation: Clin Chem. 1993 Oct;39(10):2125-9
references.pmid: 8403397
references.citation: Atherosclerosis. 1984 May-Jun;51(2-3):163-9
references.pmid: 6146320
references.citation: Arch Gen Psychiatry. 2001 Dec;58(12):1172-6
references.pmid: 11735847
references.citation: Chem Phys Lipids. 2004 Mar;128(1-2):117-24
references.pmid: 15037157
references.citation: Hum Genet. 1993 Sep;92(2):191-7
references.pmid: 8370587
references.citation: Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3495-504
references.pmid: 9437198
references.citation: Life Sci. 2000 Nov 24;68(1):29-39
references.pmid: 11132243
references.citation: Transplantation. 2002 Oct 15;74(7):974-7
references.pmid: 12394840
references.citation: Psychopharmacology (Berl). 2011 Oct;217(3):397-410
references.pmid: 21523348
references.citation: Hum Psychopharmacol. 2012 Nov;27(6):605-14
references.pmid: 24446539
references.citation: Obes Res. 2003 Oct;11(10):1200-6
references.pmid: 14569045
references.citation: Neurosci Biobehav Rev. 2011 Jan;35(3):878-93
references.pmid: 20974172
references.citation: Arterioscler Thromb. 1994 Jul;14(7):1105-13
references.pmid: 8018666
references.citation: J Clin Psychiatry. 2001;62 Suppl 23:5-12
references.pmid: 11603886
references.citation: Am J Med. 1998 Jul 6;105(1A):48S-57S
references.pmid: 9707268
references.citation: Hum Biol. 2002 Oct;74(5):659-71
references.pmid: 12495080
references.citation: Am J Hum Genet. 1985 Mar;37(2):268-85
references.pmid: 3985008
references.citation: Atherosclerosis. 1996 Mar;121(1):13-21
references.pmid: 8678918
references.citation: Prim Care Companion J Clin Psychiatry. 2009;11(1):16-20
references.pmid: 19333405
references.citation: Schizophr Res. 2006 Sep;86(1-3):1-14
references.pmid: 16842972
references.citation: J Intern Med. 2002 Jun;251(6):518-25
references.pmid: 12028507
references.citation: Am J Psychiatry. 2003 Feb;160(2):284-9
references.pmid: 12562574
references.citation: Atherosclerosis. 2000 Feb;148(2):327-35
references.pmid: 10657569
references.citation: Encephale. 2006 Mar-Apr;32(2 Pt 1):244-52
references.pmid: 16910626
references.citation: Pharm Res. 2012 Jul;29(7):1932-48
references.pmid: 22437487
references.citation: Eur J Clin Invest. 2002 Oct;32(10):738-42
references.pmid: 12406021
references.citation: Hum Biol. 1991 Apr;63(2):179-86
references.pmid: 2019410
references.citation: Eur J Epidemiol. 2001;17(8):707-13
references.pmid: 12086087
references.citation: Eur J Pharmacol. 2014 Oct 5;740:697-702
references.pmid: 24956504
references.citation: Curr Opin Lipidol. 2002 Jun;13(3):289-94
references.pmid: 12045399
references.citation: Atherosclerosis. 1999 Nov 1;147(1):167-76
references.pmid: 10525138
references.citation: Int J Neuropsychopharmacol. 2008 Sep;11(6):851-76
references.pmid: 18205981